Wrong. Retina doctors still use about 75% avastin and the rest is split between Eylea and Lucentis. Some studies show that Eylea may be a hair better then avastin or lucentis in certain conditions, other studies not really any better. Medicare data shows higher infection rates in Eylea and Lucentis treated patients (probably due to the doctor having to draw it up in the room, whereas Avastin is preloaded in compounding pharmacies under a sterile hood). Avastin $40/dose, the others $2000. Just not worth what might be a one or two letter difference in treatment results after a few years, especially in patients with poor vision in the treated eye and good vision in their other. Just doesn't make a difference in patient's activity of daily living. Eylea and Lucentis would be used even less if doctors weren't invented to use it by getting their credit card rebate and the J code markup that gives them a few percent on each $2000 dose.
Not even really better than a $40 dose of Avastin off-label. Look up protocol T 2yr. data and read it for yourself.
At least MB knows how to dilute his losses. You can only dilute the whiskey so much before the old man notices.
It just keeps getting sillier.
Haha. And they say there is more to come int he future.
that there have been unusually short spikes of big volume. Institutional selling.
And will fail miserably with "Salesforce Health Cloud". They are entering this area way to late to have any significant impact. This will be Salesforce's biggest mistake.
Doctors currently don't get paid for phone calls, patient communication, etc.. Do you really think they want to be connected to their patients 24/7 when they already work 50-60hrs/week?
CRM did rocket up last February after earnings, but this is a different environment with different expectations. They'll probably lose more money than last year and it may not settle well with investors should the environment be otherwise mediocre.
If you consider down 20% in one month "holding up incredibly strong", uhhh, I guess, well, alrighty then.
Seems to be pretty simple math.